Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Dihexa | LL-37 (Cathelicidin) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 10-20 mg daily via oral or sublingual administration. | Research indicates 50-100 mcg daily via subcutaneous injection for immune support. |
| Timing | Morning dosing preferred. Can be taken with or without food (orally active). | Morning administration preferred for immune support. Topical application directly to wound sites. |
| Cycle Duration | 2-4 week cycles with equal rest periods. Long-term safety data is extremely limited. | 4-8 week cycles. Short-term use preferred due to limited long-term safety data. |
| Evidence Level | animal_plus_anecdotal | animal_plus_anecdotal |
Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is an orally active, blood-brain barrier-permeable oligopeptide derived from angiotensin IV. It binds hepatocyte growth factor (HGF) with high affinity, inhibiting HGF dimerization and synergistically promoting c-Met receptor phosphorylation and signaling. Activation of HGF/c-Met drives procognitive effects through increased dendritic arborization, spinogenesis, and synaptogenesis via the PI3K/AKT signaling pathway. Research indicates it is approximately 10 million times more potent than BDNF for new synapse formation.
Research indicates 10-20 mg daily via oral or sublingual administration.
Morning dosing preferred. Can be taken with or without food (orally active).
2-4 week cycles with equal rest periods. Long-term safety data is extremely limited.
LL-37 is a 37-residue amphipathic helical antimicrobial peptide, the only human cathelicidin, that kills bacteria by forming tetrameric channels that perforate cytoplasmic membranes. Beyond direct antimicrobial activity, it modulates innate immunity through formyl-peptide receptor 2 (FPR2), induces chemotaxis of neutrophils and monocytes, upregulates CXCR4 and IL-8, and neutralizes bacterial endotoxins (LPS). It also promotes wound healing through keratinocyte migration and angiogenesis.
Research indicates 50-100 mcg daily via subcutaneous injection for immune support.
Morning administration preferred for immune support. Topical application directly to wound sites.
4-8 week cycles. Short-term use preferred due to limited long-term safety data.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →